Qualigen Therapeutics, Inc. - FORM S-1 - EX-23.1 - EXHIBIT 23.1 - March 23, 2015

Attached files

file filename
S-1 - FORM S-1 - Qualigen Therapeutics, Inc.t1500225-s1.htm
EX-10.27 - EXHIBIT 10.27 - Qualigen Therapeutics, Inc.t1500225_ex10-27.htm
EX-10.6 - EXHIBIT 10.6 - Qualigen Therapeutics, Inc.t1500225_ex10-6.htm
EX-10.23 - EXHIBIT 10.23 - Qualigen Therapeutics, Inc.t1500225_ex10-23.htm
EX-10.2 - EXHIBIT 10.2 - Qualigen Therapeutics, Inc.t1500225_ex10-2.htm
EX-10.13 - EXHIBIT 10.13 - Qualigen Therapeutics, Inc.t1500225_ex10-13.htm
EX-3.2 - EXHIBIT 3.2 - Qualigen Therapeutics, Inc.t1500225_ex3-2.htm
EX-3.1 - EXHIBIT 3.1 - Qualigen Therapeutics, Inc.t1500225_ex3-1.htm
EX-10.17 - EXHIBIT 10.17 - Qualigen Therapeutics, Inc.t1500225_ex10-17.htm
EX-10.4 - EXHIBIT 10.4 - Qualigen Therapeutics, Inc.t1500225_ex10-4.htm
EX-10.16 - EXHIBIT 10.16 - Qualigen Therapeutics, Inc.t1500225_ex10-16.htm
EX-10.25 - EXHIBIT 10.25 - Qualigen Therapeutics, Inc.t1500225_ex10-25.htm
EX-10.21 - EXHIBIT 10.21 - Qualigen Therapeutics, Inc.t1500225_ex10-21.htm
EX-10.1 - EXHIBIT 10.1 - Qualigen Therapeutics, Inc.t1500225_ex10-1.htm
EX-10.18 - EXHIBIT 10.18 - Qualigen Therapeutics, Inc.t1500225_ex10-18.htm
EX-10.22 - EXHIBIT 10.22 - Qualigen Therapeutics, Inc.t1500225_ex10-22.htm
EX-10.14 - EXHIBIT 10.14 - Qualigen Therapeutics, Inc.t1500225_ex10-14.htm
EX-4.5 - EXHIBIT 4.5 - Qualigen Therapeutics, Inc.t1500225_ex4-5.htm
EX-10.20 - EXHIBIT 10.20 - Qualigen Therapeutics, Inc.t1500225_ex10-20.htm
EX-10.3 - EXHIBIT 10.3 - Qualigen Therapeutics, Inc.t1500225_ex10-3.htm
EX-10.19 - EXHIBIT 10.19 - Qualigen Therapeutics, Inc.t1500225_ex10-19.htm
EX-10.9 - EXHIBIT 10.9 - Qualigen Therapeutics, Inc.t1500225_ex10-9.htm
EX-10.5 - EXHIBIT 10.5 - Qualigen Therapeutics, Inc.t1500225_ex10-5.htm
EX-10.10 - EXHIBIT 10.10 - Qualigen Therapeutics, Inc.t1500225_ex10-10.htm
EX-10.24 - EXHIBIT 10.24 - Qualigen Therapeutics, Inc.t1500225_ex10-24.htm
EX-10.8 - EXHIBIT 10.8 - Qualigen Therapeutics, Inc.t1500225_ex10-8.htm
EX-4.4 - EXHIBIT 4.4 - Qualigen Therapeutics, Inc.t1500225_ex4-4.htm
EX-10.15 - EXHIBIT 10.15 - Qualigen Therapeutics, Inc.t1500225_ex10-15.htm
EX-4.3 - EXHIBIT 4.3 - Qualigen Therapeutics, Inc.t1500225_ex4-3.htm
EX-10.26 - EXHIBIT 10.26 - Qualigen Therapeutics, Inc.t1500225_ex10-26.htm
EX-4.2 - EXHIBIT 4.2 - Qualigen Therapeutics, Inc.t1500225_ex4-2.htm
EX-21.1 - EXHIBIT 21.1 - Qualigen Therapeutics, Inc.t1500225_ex21-1.htm
EX-10.28 - EXHIBIT 10.28 - Qualigen Therapeutics, Inc.t1500225_ex10-28.htm
EX-10.12 - EXHIBIT 10.12 - Qualigen Therapeutics, Inc.t1500225_ex10-12.htm
EX-10.11 - EXHIBIT 10.11 - Qualigen Therapeutics, Inc.t1500225_ex10-11.htm

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

As independent registered public accountants, we hereby consent to the use in this Registration Statement on Form S-1 and related Prospectus of our report dated March 13, 2015, relating to the financial statements of Ritter Pharmaceuticals, Inc., (which report includes an explanatory paragraph relating to the uncertainty of the Company’s ability to continue as a going concern) and to the reference to our Firm under the caption “Experts” in this Registration Statement.

/s/ Mayer Hoffman McCann P.C.       

 

Orange County, California
March 20, 2015

 

 

Qualigen Therapeutics, Inc. Reports